ecancer

Latest in diagnostics in EGFR mutated NSCLC

Dr Neal Lindeman - Brigham and Women's Hospital, Boston, USA

3 Dec 2021

WCLC 2021: Epidemiology of MET Exon 14 mutations

Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinger

19 Oct 2021

OncoAlert and ecancer weekly round up for October 11th - October 16, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

18 Oct 2021

ESMO 2021: Latest in EGFR mutated advanced NSCLC

Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera

11 Oct 2021

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA

Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA

6 Oct 2021

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC

Dr Pascale Tomasini and Dr Catherine Shu

27 Sep 2021

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

23 Sep 2021

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain

23 Sep 2021

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada

22 Sep 2021

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA

21 Sep 2021

OncoAlert and ecancer - ESMO 2021 Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

19 Sep 2021

OncoAlert and ecancer - ESMO 2021 Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

18 Sep 2021

More from ecancer